Inadequate responders to osteoporosis treatment: Proposal for an operational definition

Osteoporosis International

Volumn 19, Issue 11, 2008, Pages 1511-1516

  Diez Perez A ^a,c   Gonzalez Macias J ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

BMD; Fracture; Osteoporosis; Treatment; Treatment response

Indexed keywords

VITAMIN D;

BONE DENSITY; BONE FRAGILITY; BONE REMODELING; BONE TURNOVER; CALCIUM INTAKE; FRACTURE; HUMAN; OSTEOPOROSIS; PATIENT ATTITUDE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE; TERMINOLOGY AS TOPIC; TREATMENT FAILURE;

EID: 53549104140     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0659-2     Document Type: Review

References (52)

1. JA Cramer DT Gold SL Silverman 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023 1031
2. JJ Caro KJ Ishak KF Huybrechts 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003 1008
3. ES Siris ST Harris CJ Rosen 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022
4. DM Black SR Cummings DB Karpf 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541
5. ST Harris NB Watts HK Genant 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352
6. B Ettinger DM Black BH Mitlak 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637 645
7. CH Chesnut III S Silverman K Andriano 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group Am J Med 109 267 276
8. PJ Meunier C Roux E Seeman 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 468
9. RM Neer CD Arnaud JR Zanchetta 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441
10. S Adami G Isaia G Luisetto 2006 Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study J Bone Miner Res 21 1565 1570
11. PW Hugen N Langebeek DM Burger 2002 Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring J Acquir Immune Defic Syndr 30 324 334
12. PT Nieuwkerk FJ Oort 2005 Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis J Acquir Immune Defic Syndr 38 445 448
13. JC Walsh S Mandalia BG Gazzard 2002 Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome AIDS 16 269 277
14. JH Arnsten PA Demas H Farzadegan 2001 Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring Clin Infect Dis 33 1417 1423
15. CV Fletcher MA Testa RC Brundage 2005 Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359 J Acquir Immune Defic Syndr 40 301 306
16. JT Harrington LG Ste-Marie ML Brandi 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 129 135
17. HA Pols D Felsenberg DA Hanley 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group Osteoporos Int 9 461 468
18. E Seeman 2007 Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy Bone 41 308 317
19. Dempster DW (2002) Bone remodeling. In: Coe FL, Favus MJ (eds) (2002) Disorders of bone and mineral metabolism, 2nd edn. Lippincott Williams and Wilkins, Baltimore, pp 315-343
20. A Diez-Perez J Gonzalez-Macias F Marin 2007 Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound Osteoporos Int 18 629 639
21. S Baim CR Wilson EM Lewiecki 2005 Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry J Clin Densitom 8 371 378
22. CC Gluer 1999 Monitoring skeletal changes by radiological techniques J Bone Miner Res 14 1952 1962
23. MC Lodder WF Lems HJ Ader 2004 Reproducibility of bone mineral density measurement in daily practice Ann Rheum Dis 63 285 289
24. S Sarkar JY Reginster GG Crans 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk J Bone Min Res 19 394 401
25. RD Chapurlat L Palermo P Ramsay SR Cummings 2005 Risk of fracture among women who lose bone density during treatment with alendronate: the Fracture Intervention Trial Osteoporos Int 16 842 848
26. L Lenchik GM Kiebzak BA Blunt 2002 International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. What is the role of serial bone mineral density measurements in patient management J Clin Densitom 5 Suppl S29 S38
27. DC Bauer DM Black P Garnero 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial J Bone Miner Res 19 1250 1258
28. E Barrett-Connor 1991 Nutrition epidemiology: how do we know what they ate Am J Clin Nutr 54 Suppl 1 182S 187S
29. S Gaugris RP Heaney S Boonen 2005 Vitamin D inadequacy among post-menopausal women: a systematic review QJM 98 667 676
30. T Dixon P Mitchell T Beringer 2006 An overview of the prevalence of 25-hydroxy-vitamin D inadequacy amongst elderly patients with or without fragility fracture in the United Kingdom Curr Med Res Opin 22 405 415
31. CH Wilkins SJ Birge 2005 Prevention of osteoporotic fractures in the elderly Am J Med 118 1190 1195
32. C Jackson S Gaugris SS Sen 2007 The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis QJM 100 185 192
33. A Del Puente A Scognamiglio E Itto 2000 Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis J Rheumatol 27 1980 1983
34. GA Heckman A Papaioannou RJ Sebaldt 2002 Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates BMC Musculoskelet Disord 3 6
35. AM Sawka JD Adachi G Ioannidis 2003 What predicts early fracture or bone loss on bisphosphonate therapy J Clin Densitom 6 315 322
36. EM Lewiecki 2003 Nonresponders to osteoporosis therapy J Clin Densitom 6 307 314
37. National Institute for Clinical Excellence (2004) Final appraisal determination-secondary prevention of osteoporotic fragility fractures in postmenopausal women. http://www.nice.org.uk/page.aspx?o = 115560
38. F Jakob F Marin E Martin-Mola 2006 Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO) QJM 99 531 543
39. BM Obermayer-Pietsch T Nickelsen F Marin 2006 Response of BMD to 24 months of teriparatide (rhPTH 1-34) in patients with and without prior antiresorptive treatment: final results from the EUROFORS Study J Bone Miner Res 21 Suppl 1 S43
40. S Sarkar BH Mitlak M Wong 2002 Relationship between bone mineral density and incident vertebral fracture risk with raloxifene therapy J Bone Min Res 17 1 10
41. S Khosla 2003 Surrogates for fracture endpoints in clinical trials J Bone Min Res 18 1146 1149
42. AI Sebba SL Bonnick R Kagan 2004 Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis Curr Med Res Opin 20 2031 2041
43. L Ferrar G Jiang G Armbrecht 2007 Is short vertebral height always an osteoporotic fracture? The Osteoporosis and Ultrasound Study (OPUS) Bone 41 5 12
44. SD Ohlendorff CL Tofteng JE Jensen 2007 Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment Pharmacogenet Genomics 17 555 567
45. PB Rapuri JC Gallagher JA Knezetic 2006 Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen Maturitas 53 371 379
46. T Yahata J Quan N Tamura 2005 Association between single nucleotide polymorphisms of estrogen receptor alpha gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women Hum Reprod 20 1860 1866
47. CL Tofteng B Abrahamsen JE Jensen 2004 Two single nucleotide polymorphisms in the CYP17 and COMT Genes-relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study Calcif Tissue Int 75 123 132
48. NA Morrison PM George T Vaughan 2005 Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis Pharmacogenet Genomics 15 127 135
49. D Steines C Arnaud S Liew 2005 Predicting hip fracture in a sub-group of subjects from the study of osteoporotic fractures using automated structural measurements of proximal femur in pelvic radiographs J Bone Miner Res 20 Suppl 1 F090
50. F Rivadeneira MC Zillikens CE De Laet 2007 Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam Study J Bone Miner Res 22 1781 1790
51. CJ Hernandez A Gupta TM Keaveny 2006 A biomechanical analysis of the effects of resorption cavities on cancellous bone strength J Bone Miner Res 21 1248 1255
52. GA Ladinsky B Vasilic AM Popescu 2008 Trabecular structure quantified with the MRI-based virtual bone biopsy in postmenopausal women contributes to vertebral deformity burden independent of areal vertebral BMD J Bone Miner Res 23 64 74